Priliximab (CEN 000029) is an anti-CD4 humanized monoclonal antibody. Priliximab binds to CD4 on the surface of T cells, resulting in a significant and sustained reduction in circulating CD4+ T cells. Priliximab can be used in research of rheumatoid arthritis (RA)[1].
CAS Number:
[147191-91-1]
Target:
Transmembrane Glycoprotein
Application Notes:
MCE Product type: Inhibitory Antibodies
* VAT and and shipping costs not included. Errors and price changes excepted
